Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1656 in Transplantation with Diabetes to Promote Immune Tolerance
2019-001587-30Phase 2Unknown
- Sponsor
- Queen Mary University of London
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing AZD1656 with Placebo (2 arms). Primary endpoint: Change in mean peripheral regulatory T cell number. Status: unknown.
02
Drugs
AZD1656
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-001587-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001587-30.